Lukas Schüpbach

MSc / Board Member

Lukas Schüpbach entered the microbiome market as CEO of Bacthera from 2020–2023. He developed the joint venture between Lonza & Chr. Hansen to become the leading CDMO in the market. Prior he has held several senior R&D, Operations, Strategy, Business Development, and Finance leadership positions at Syngenta, Novartis, and a Roivant Sciences portfolio company and has developed his entrepreneurial skills as a founder of Innojection, an Ag-Tech start-up that was sold to a Flagship Pioneering company in 2019. He started his career as a Principal in Management Consulting at PwC. Lukas is currently a board member of BaselArea Business & Innovation.

He holds a master's degree in Business & General Management from the University of Basel and a master's degree in Economics from HEC Lausanne. He is also an alumnus of several executive management programs at IMD and Harvard Business School.